Challenges for structure-based HIV vaccine design
暂无分享,去创建一个
[1] J. Sodroski,et al. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein , 1995, Journal of virology.
[2] Mark Connors,et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.
[3] N. Sullivan,et al. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 , 1993, Journal of virology.
[4] J. Shiver,et al. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions , 2008, Proceedings of the National Academy of Sciences.
[5] H. Ellens,et al. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[6] L. Morris,et al. The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.
[7] Douglas D. Richman,et al. Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors , 2007, Journal of Virology.
[8] David Yang,et al. The N-Terminal V3 Loop Glycan Modulates the Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors , 2000, Journal of Virology.
[9] A. Pinter. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. , 2007, Current HIV research.
[10] Peter D. Kwong,et al. Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope , 2004, Journal of Virology.
[11] D R Burton,et al. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off , 1997, Journal of virology.
[12] Yang Liu,et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[13] H. Katinger,et al. The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. , 2003, Advances in experimental medicine and biology.
[14] Gira Bhabha,et al. Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.
[15] Wei Zhang,et al. Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 2. Expression, purification, and characterization of recombinant single chain antibodies. , 2007, Biochemistry.
[16] L. Stamatatos,et al. V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies , 2000, Journal of Virology.
[17] John R. Mascola,et al. Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.
[18] D. Montefiori,et al. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. , 2009, Virology.
[19] H. Katinger,et al. The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.
[20] K. Tomer,et al. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. , 2000, Biochemistry.
[21] T. Mizuochi,et al. Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. , 1988, The Biochemical journal.
[22] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[23] Stephen D Fuller,et al. Cryo-Electron Tomographic Structure of an Immunodeficiency Virus Envelope Complex In Situ , 2006, PLoS pathogens.
[24] J. Sodroski,et al. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.
[25] J. Moore,et al. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures , 1994, Journal of virology.
[26] J. Sodroski,et al. Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity , 1991, Journal of virology.
[27] J. Hoxie,et al. Envelope Glycoprotein Incorporation, Not Shedding of Surface Envelope Glycoprotein (gp120/SU), Is the Primary Determinant of SU Content of Purified Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus , 2002, Journal of Virology.
[28] Sriram Subramaniam,et al. Electron Tomography of the Contact between T Cells and SIV/HIV-1: Implications for Viral Entry , 2007, PLoS pathogens.
[29] L. Stamatatos,et al. N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies , 2004, Journal of Virology.
[30] W. Weis,et al. Structural basis of lectin-carbohydrate recognition. , 1996, Annual review of biochemistry.
[31] Christoph Grundner,et al. Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.
[32] Xuesong Yu,et al. Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[33] J. Hoxie,et al. Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. , 2008, Virology.
[34] W. Weis. Cell-surface carbohydrate recognition by animal and viral lectins. , 1997, Current opinion in structural biology.
[35] Kenneth A. Taylor,et al. Cryoelectron Tomography of HIV-1 Envelope Spikes: Further Evidence for Tripod-Like Legs , 2008, PLoS pathogens.
[36] Renate Kunert,et al. Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.
[37] Sara Sandin,et al. Structure and flexibility of individual immunoglobulin G molecules in solution. , 2004, Structure.
[38] K. Roux,et al. Flexibility of human IgG subclasses. , 1997, Journal of immunology.
[39] J. Binley,et al. Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.
[40] Christoph Grundner,et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. , 2003, Virology.
[41] A. West,et al. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10 , 2009, Proceedings of the National Academy of Sciences.
[42] John P. Moore,et al. Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. , 2009, Biochemistry.
[43] R. Doms,et al. A Yeast Glycoprotein Shows High-Affinity Binding to the Broadly Neutralizing Human Immunodeficiency Virus Antibody 2G12 and Inhibits gp120 Interactions with 2G12 and DC-SIGN , 2009, Journal of Virology.
[44] A. Trkola,et al. Antibody responses in primary HIV-1 infection , 2008, Current opinion in HIV and AIDS.
[45] J. Sodroski,et al. Stoichiometry of Envelope Glycoprotein Trimers in the Entry of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.
[46] J. Hoxie,et al. Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma , 2008, Journal of Virology.
[47] James Paulson,et al. Phage-display selection of a human single-chain fv antibody highly specific for melanoma and breast cancer cells using a chemoenzymatically synthesized G(M3)-carbohydrate antigen. , 2002, Journal of the American Chemical Society.
[48] Q. Sattentau,et al. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. , 1990, Science.
[49] G. Sapiro,et al. Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.
[50] E. Go,et al. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. , 2008, Journal of proteome research.
[51] J. Skehel,et al. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.
[52] H. Katinger,et al. Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. , 2007, Biochemistry.
[53] D. Burton. Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.
[54] D. Burton,et al. A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120 , 2008, Journal of Virology.
[55] D. Ho,et al. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.
[56] David F. Smith,et al. An Engineered Saccharomyces cerevisiae Strain Binds the Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody 2G12 and Elicits Mannose-Specific gp120-Binding Antibodies , 2008, Journal of Virology.
[57] J. Kappes,et al. Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.
[58] Lynn Morris,et al. Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.
[59] Tongqing Zhou,et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.
[60] Yifan Cheng,et al. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies , 2008, Proceedings of the National Academy of Sciences.
[61] F. Bibollet-Ruche,et al. Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection , 2007, Journal of Virology.
[62] Q. Sattentau,et al. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4 , 1991, Journal of virology.
[63] Uwe Karsten,et al. Multivalent scFv display of phagemid repertoires for the selection of carbohydrate-specific antibodies and its application to the Thomsen-Friedenreich antigen. , 2004, Journal of molecular biology.
[64] Boguslaw Stec,et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.
[65] P. Rios,et al. Freezing immunoglobulins to see them move. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[66] R. Desrosiers,et al. Glycosylation of gp41 of Simian Immunodeficiency Virus Shields Epitopes That Can Be Targets for Neutralizing Antibodies , 2008, Journal of Virology.
[67] H. Katinger,et al. A peptide inhibitor of HIV‐1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120 , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[68] S. Ohlson,et al. Transiently binding antibody fragments against Lewis x and sialyl-Lewis x. , 2006, Journal of immunological methods.
[69] Chi-Huey Wong,et al. Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN , 2008, Proceedings of the National Academy of Sciences.
[70] B. Berkhout,et al. The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion , 2008, Retrovirology.
[71] Barbra A. Richardson,et al. Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses , 2007, Journal of Virology.
[72] Robyn L Stanfield,et al. Contrasting IgG structures reveal extreme asymmetry and flexibility. , 2002, Journal of molecular biology.
[73] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[74] Peter D. Kwong,et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site , 2005, The Journal of experimental medicine.
[75] V. Brusic,et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. , 2008, Immunity.
[76] J. Sodroski,et al. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 , 1994, Journal of virology.
[77] Renate Kunert,et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. , 2005, Immunity.
[78] D. Burton,et al. Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. , 2007, Journal of molecular biology.
[79] P. S. Kim,et al. HIV Entry and Its Inhibition , 1998, Cell.
[80] J. Sodroski,et al. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody , 1993, Journal of virology.
[81] D. Burton,et al. Natural Resistance of Human Immunodeficiency Virus Type 1 to the CD4bs Antibody b12 Conferred by a Glycan and an Arginine Residue Close to the CD4 Binding Loop , 2008, Journal of Virology.
[82] J. Lifson,et al. Distribution and three-dimensional structure of AIDS virus envelope spikes , 2006, Nature.
[83] J. McKeating,et al. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain , 1995, Journal of virology.
[84] J. Mascola,et al. Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies , 2008, Journal of Virology.
[85] Ping Zhu,et al. Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition , 2003, Science.
[86] Robyn L Stanfield,et al. Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[87] Richard T. Wyatt,et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.
[88] Reed J. Harris,et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.
[89] Pojen P. Chen,et al. The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes1 , 2007, The Journal of Immunology.
[90] Peter D. Kwong,et al. The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.